ProfIlaxis de los tumores superficiales de vejiga estadio T1 con 27 mg. de BCG semanal durante seis semanas

Archivos Espanoles de Urologia

Volumn 52, Issue 7, 1999, Pages 760-768

  Calvo, José Luis Moyano ^a,b   Gámiz, Antonio Ortíz ^a   Díaz, Ángel Romero ^a   Sánchez, Ernesto Sánchez ^a   Palenciano, Esteban Blanco ^a   Rodríguez, José María Arribas ^a   Fernández, Jesús Castiñeiras ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b NONE   (Spain)

Author keywords

BCG; Bladder cancer; Prophylaxis

Indexed keywords

BCG VACCINE; EPIRUBICIN; INTERFERON; MITOMYCIN; THIOTEPA;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER PREVENTION; CANCER STAGING; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT;

BCG VACCINE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0008850198     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. HERR, H.W.; JAKSE, G.; SHEINFELD, J.: "El tumor vesical T1." En: Casos prácticos de Urología (edición española), 3: 1, 1996.
2. PAEZ BORDA, A.; MARTÍN OSES, E.; DE LA CAL LÓPEZ, M. y cols.: "Análisis de los factores pronósticos en los tumores superficiales de vejiga." Arch. Esp. Urol., 50: 121, 1997.
3. LUTZEYER, W.; RUBBEN, W.; DAHM, H.: "Prognostic parameters in superficial bladder cancer: an analysis of 315 cases." J. Urol., 127: 250, 1982.
4. KAUBISCH, S.; LUM, B.L.; REESE, J. y cols.: "Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion." J. Urol., 146: 28, 1991.
5. MARTINEZ PIÑEIRO, J.A.; JIMENEZ LEON, J.; MARTINEZ PIÑERO, L. y cols.: "Bacillus Calmette-Guerin versus doxorrubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer." J. Urol., 143: 502, 1990.
6. HERR, H.W.; LAUDONE, V.P.; WITHMORE, W.F. Jr.: "An overview of intravesical therapy for superficial bladder tumors." J. Urol., 138: 1363, 1987.
7. RINTALA, E.; JAUHIAINEN, K.; ALFTHAN, O. and THE FINNBLADDER GROUP: "Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer." Eur. Urol., 20: 19, 1991.
8. VETO, P.D.S.; WITJES, J.A.; WITJES, N.P.J. y cols.: "A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin-TICE and bacillus Calmette-Guerin-RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder." J. Urol., 153: 929, 1995.
9. JIMENEZ CRUZ, J.F.; VERA DONOSO, C.D.; LEIVA, O. y cols.: "Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha." Urology, 50: 529, 1997.
10. LAMM DL, VAN DER MEIJDEN PM, MORALES A y cols.: "Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer." J. Urol., 147: 596, 1992.
11. MORALES, A.; CURTIS NICKEL, J.; WILSON, J.W.L.: "Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer." J. Urol., 147: 1256, 1992.
12. MARTINEZ PIÑEIRO, J.A., MARTÍNEZ PIÑEIRO, L.: "BCG update: intravesical therapy." Eur. Urol., 31(suppl. 1): 31, 1997.
13. PAGANO, F.; BASSI, P.; PIAZZA, N. y cols.: "Improving the efficacy of BCG immunotherapy by dose reduction." Eur. Urol., 27 (suppl. 1): 19, 1995.
14. HURLE, R.; LOSA, A.; RAINIERI, A.: "Low dose Pasteur Bacillus Calmette Guerin regimen in stage T1, grade 3 bladder cancer therapy." J. Urol., 156: 1602, 1996.
15. RIVERA, P.; CAFFARENA, E.; CORNEJO, M. y cols.: "Microdosis de vacuna BCG como profilaxis en el cancer de vejiga etapa T1." Actas Urol. Esp., 17: 243, 1993.
16. MORA, M.; NAVARRO, J.; ARRIZABALAGA, M. y cols.: "Cáncer vesical superficial con alto riesgo de recidiva: resultados comparativos entre BCG, interferon y mitomicina C." Poster 89 del LIX Congreso Nacional de Urología. Sitges 1994
17. MACK, D.; FRICK, J.: "Five year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high risk superficial bladder cancer." Urology, 45: 958, 1995.
18. DUARTE, J.M.; PASSAS, J.; GARCÍA LUZÓN, A. y cols.: "BCG en la inmunoprofilaxis del tumor vesical superfical de alto riesgo. Análisis de una serie de 89 casos." Comunicación n° 81 del LXI Congreso Nacional de Urología. Santander 1996
19. IANTORNO, R.; NICOLAI, M.; CRINITI, P. y cols.: "The option therapy for stage T1G3 superficial bladder cancer: eight years of low dose bacillus Calmette-Guerin." SIU 24th World Congress 1997; Abstract 177.
20. LEBRET, T.; GAUDEZ, F.; HERVE, J.M.: "Low dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success." Eur. Urol., 34: 67, 1998.
21. CORTI ORTIZ, D.; RIVERA GARAY, P.; AVILES JASSE, J. y cols.: "Profilaxis del cáncer vesical superficial con 1 mg. de BCG endovesical: comparación con otras dosis." Actas Urol. Esp., 17: 239, 1993.
22. COPLEN, D.E.; MARCUS, M.D.; MYERS, J.A. y cols.: "Long-term follow up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor." J. Urol., 144: 625, 1990.
23. EURE, G.R.; CUNDIFF, M.R.; SCHLELHAMMER, P.F.: "Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer." J. Urol., 147: 376, 1992.
24. COOKSON, M.S.; SAROSDY, M.F.: "Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy."J. Urol., 148:797, 1992.
25. PANSADORO, V.; EMILIOZZI, P.; DEFIDIO, L. y cols.: "Bacillus Calmette-Guerin in the treatment of stage T1G3 transitional cell carcinoma of the bladder: long-term results." J. Urol., 154: 2054, 1995.
26. VILCHES, E.; AMAYA, J.; DOMINGUEZ, M. y cols.: "Mitomicina C/BCG: estudio comparativo en la profilaxis de tumores vesicales superficiales de riesgo intermedio." Comunicación n° 78 del LXI Congreso Nacional de Urología. Santander 1996
27. DE PAULA, F.; BRISCIANI, A.; DONADIO, D.: "Long-term follow-up of G3T1 bladder tumors treated with intravesical BCG." SIU 24th World Congress 1997; Abstract 120.
28. KULKARNI; J.N.; DESAI, S.M.; TONGAONKAR, H.B.: "Impact of intravesical BCG immunotherapy of T1 bladder TCC and analysis of prognostic factors determining the response." SIU 24th World Congress 1997; Abstract 178.
29. PALOU, J.; ROSALES, A.; CHECHILE, G.: "Long-term follow-up of 98 patients with T1G3 transitional cell carcinoma of the bladder treated with BCG." SIU 24th World Congress 1997; Abstract 140.
30. CABALLERO, J.M.; BORRAT, P.; BASTUS, R. y cols.: "Bacillus Calmette-Guerin therapy for stage T1 grade 3 carcinoma of the bladder." SIU 24th World Congress 1997; Abstract 162.
31. RICO, J.; BLASCO, P.; CAMACHO, E. y cols.: "Tumor vesical pT1 GII. Eficacia del tratamiento conservador mediante inmunoprofilaxis endovesical con BCG." Poster n° 169 del LXIII Congreso Nacional de Urología. Cádiz 1998.
32. SAROSDY, M.F.; LAMM, D.L.: "Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial baldder cancer. J. Urol., 142: 719, 1989.
33. KAVOUSSI, L.R.; TORRENCE, R.J.; GIELEN, D.P. y cols.: "Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors." J. Urol., 139: 935, 1988.
34. LAMM, D.E.; BEUMENSTEIN, B.; SAROSDY, M. y cols.: "Significant long-term patient benefit with BCG maintenance therapy." J. Urol., 157: 831, 1997.
35. HUDSON, M.E.; RATLIFF, T.L.; GILLEN, P. y cols.: "Single course versus maintenance therapy for superficial bladder tumors: a prospective, randomized trial." J. Urol., 138: 295, 1987.
36. BADALAMENT, R.A.; HERR, H.W.; WONG, G.Y. y cols.: "A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer." J. Clin. Oncol., 5:441, 1987.
37. OSCA, J.M.; GOMEZ-FERRER, A.; FUESTER, A. y cols.: "Estudio prospectivo randomizado del tratamiento del tumor vesical superficial con RTU y quimioterapia endovesical versus RTU y Adriamicina dosis única versus RTU sin otro tratamiento." Poster n° 170 del LXIII Congreso Nacional de Urología. Cádiz 1998.